P4A experts regularly share their unique perspectives that inform and challenge the norm through articles and white papers.
Coming up at #WODCUSA is a panel on “Articulating the value of curative therapies for pricing and reimbursement” which will be moderated by Akshay Kumar, Partner here at #P4A. The panel will live so we encourage you to join at 09:50 ET(14:50 UK time)and any questions you may have
Evert Van Lente,#AOK shared his ideal future for OMP legislation.Whilst we at #P4A are fully aligned with the vision for a sustainable #raredisease world,there needs to be a balance struck between payer affordability,patientaccess and a fair return on investment for manufacturers
Make sure to check out our very own Sophie Schmitz’s panel on Successfully navigating a new era: outlooks on future access to treatments, cures and clinical trials for rare disease patients at Wednesday, August 26, 2020 4:05 PM (UK time). #wodcusa #WODC #Raredisease
France to place restrictions on the Nominative ATU. In our blog we explore the reasons behind this and the implications for industry who previously sought this route as an early revenue opportunity.
#France #ATU #MarketAccess